This HTML5 document contains 80 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01421/identifier/chemspider/
n15http://linked.opendata.cz/resource/AHFS/
n8http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01421/identifier/wikipedia/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01421/identifier/pharmgkb/
n24http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB01421/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n23http://www.rxlist.com/cgi/generic/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01421/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01421/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01421/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01421
rdf:type
n3:Drug
n3:description
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
n3:generalReferences
# Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure. 2001 Aug;9(8):647-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11587639
n3:group
approved investigational
n3:indication
For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
owl:sameAs
n13:DB01421 n24:DB01421
dcterms:title
Paromomycin
adms:identifier
n10:165580 n11:46505391 n17:61570-529-10 n18:145115 n19:DB01421 n25:PA164784023 n26:Paromomycin_sulfate
n3:mechanismOfAction
Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death.
n3:packager
n5:271B48DA-363D-11E5-9242-09173F13E4C5 n5:271B48DB-363D-11E5-9242-09173F13E4C5 n5:271B48D9-363D-11E5-9242-09173F13E4C5 n5:271B48DC-363D-11E5-9242-09173F13E4C5
n3:synonym
Paromomycin i Paromomycine Hydroxymycin R 400 Aminosidin Paucimycinum Aminosidine Paromomicina Paromomycinum Catenulin PAROMOMYCIN (1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside R-400 Crestomycin Monomycin a Paucimycin Estomycin Neomycin e Zygomycin a1
n14:hasAHFSCode
n15:08-30-04
n3:foodInteraction
Take with food.
n3:salt
n3:synthesisReference
Federico Arcamone, Giuseppe Cassinelli, "Paromomycin derivatives and process for the preparation thereof." U.S. Patent US4021601, issued October, 1967.
n7:hasConcept
n8:M0015969
foaf:page
n22:paromomycin.html n23:humatin.htm
n3:IUPAC-Name
n4:271B48E3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B48E9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B48E8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B48E5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B48E6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B48E7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B48E1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B48DF-363D-11E5-9242-09173F13E4C5 n4:271B48E2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B48E0-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n16:A07AA06
n3:H-Bond-Acceptor-Count
n4:271B48EF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B48F0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B48EA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B48EB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B48ED-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B48EC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B48EE-363D-11E5-9242-09173F13E4C5
n3:absorption
Poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
7542-37-2
n3:category
n3:containedIn
n6:271B48DD-363D-11E5-9242-09173F13E4C5 n6:271B48DE-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B48F5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B48F7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B48F8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B48F4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B48F3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B48F6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B48E4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B48F1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B48F2-363D-11E5-9242-09173F13E4C5